regulatoryaffairs.pharmaceutical-business-review.com Report : Visit Site

Technical data of the regulatoryaffairs.pharmaceutical-business-review.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host regulatoryaffairs.pharmaceutical-business-review.com. Currently, hosted in United Kingdom and its service provider is Progressive Digital Media .

the related websites

alliancechemicals.com technicalpaintservices.co.uk regulatory-affairs.pl healthcareimprovementscotland.org metro.co.uk crazyvegas.com annelibush.com film.thedigitalfix.com classtools.net freeindex.co.uk sparknotes.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.0, 15_16 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

-- jump to page content accessibility log in or register for enhanced features | forgotten password? or register for enhanced features-- white papers | suppliers | events | report store | companies | dining club | medical devices | videos production & manufacturing fine & speciality chemicals manufacturing process & production otc digital transformation intelligent edge enable digital optimise core -- drug research drug delivery drug discovery & development digital transformation intelligent edge enable digital optimise core -- contract research & services clinical trials contract research contract services digital transformation intelligent edge enable digital optimise core -- automation it & software laboratory instrumentation digital transformation intelligent edge enable digital optimise core -- inward investment packaging regulatory affairs digital transformation intelligent edge enable digital optimise core -- medical devices -- regulatory affairs all pbr | regulatory affairs regulatory affairs home | news | white papers | suppliers | companies return to: pbr home | regulatory affairs select a pharmaceutical sector ------------------------ fine & speciality chemicals manufacturing process & production otc ------------------------ drug delivery drug discovery & development ------------------------ clinical trials contract research contract services ------------------------ it & software laboratory instrumentation ------------------------ inward investment packaging regulatory affairs pharmaceutical business review regulatory affairs fda advisory committee votes against approving gsk’s mepolizumab to treat copd by pbr staff writer the pulmonary allergy drugs advisory committee of the us food and drug administration (fda) has voted against recommending glaxosmithkline’s (gsk) mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment to reduce exacerbations in patients with chronic obstructive pulmonary disease (copd) guided by blood eosinophil counts. regulatory affairs > news futura medical seeks uk approval for topical pain relief product futura medical announced that its uk commercialisation partner for tpr100, one of the company's novel topical pain relief products, has filed the product's marketing authorisation application with the uk medicines and healthcare products regulatory agency. regulatory affairs > news agios pharmaceuticals secures fda nod for leukemia treatment tibsovo by pbr staff writer agios pharmaceuticals has secured approval from the us food and drug administration (fda) for its tibsovo (ivosidenib) to treat adult patients with relapsed or refractory acute myeloid leukemia (r/r aml) with a susceptible isocitrate dehydrogenase-1 (idh1) mutation. regulatory affairs > news see more regulatory affairs news latest regulatory affairs news and insight view all regulatory affairs news or find news targeted to your interests fda accepts immunomedics’ bla and grants priority review for sacituzumab govitecan to treat metastatic triple-negative breast cancer immunomedics announced that the us food and drug administration (fda) has accepted its biologics license application (bla) for filing and granted priority review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mtnbc) who previously received at least two prior therapies for metastatic disease. regulatory affairs > news indivior wins us court order blocking dr. reddy's sale of generic opioid treatment by pbr staff writer a us court has approved indivior’s preliminary injunction (pi) preventing dr. reddy's laboratories (drl) from marketing of generic opioid addiction treatment. regulatory affairs > news siga technologies gets fda nod for tpoxx to treat smallpox by mdbr staff writer siga technologies has secured approval from the us food and drug administration (fda) for its tpoxx (tecovirimat) for the treatment of smallpox. regulatory affairs > news fda grants priority review to merck’s sbla for keytruda to treat advanced hepatocellular carcinoma merck announced that the us food and drug administration (fda) has accepted and granted priority review for a new supplemental biologics license application (sbla) seeking approval for anti-pd-1 therapy, keytruda, as a treatment for previously treated patients with advanced hepatocellular carcinoma (hcc). regulatory affairs > news biocryst terminates merger deal with idera pharmaceuticals by pbr staff writer biocryst pharmaceuticals has failed to get approval from the stockholders for its merger deal with idera pharmaceuticals. regulatory affairs > news amryt secures funding approval from nhs england for bad cholesterol treatment by pbr staff writer biopharmaceutical firm amryt has secured approval for funding from nhs england for its bad cholesterol treatment, lojuxta (lomitapide). regulatory affairs > news ema recalls certain heart drugs containing valsartan over safety fears by pbr staff writer the european medicines agency (ema) has recalled certain heart drugs containing valsartan across the european union (eu) over possible contamination with a cancer-causing substance. regulatory affairs > news alliance pharma secures uk approval for nausea drug diclectin by pbr staff writer alliance pharma has secured approval for diclectin in the uk from the medicines and healthcare products regulatory agency (mhra) for the treatment of nausea and vomiting in pregnant women. regulatory affairs > news ec approves expanded indication for bms’ sprycel bristol-myers squibb (bms) has announced that the european commission (ec) has expanded the indication for sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml) in chronic phase (cp), and to include a powder for oral suspension formulation. regulatory affairs > news ema accepts clovis’ application for expanded indication of rubraca to treat ovarian cancer by pbr staff writer the european medicines agency (ema) has accepted clovis oncology’s marketing application for a new indication of rubraca (rucaparib) as maintenance treatment for women with recurrent ovarian cancer. regulatory affairs > news view all regulatory affairs news or find news targeted to your interests 0' report store -- in the spotlight nsf human error prevention: solutions and answers fda advisory committee votes against approving gsk’s mepolizumab to treat copd futura medical seeks uk approval for topical pain relief product agios pharmaceuticals secures fda nod for leukemia treatment tibsovo fda accepts immunomedics’ bla and grants priority review for sacituzumab govitecan to treat metastatic triple-negative breast cancer inside regulatory affairs regulatory affairs white papers greater copenhagen healthtech brief greater copenhagen regulatory affairs > white papers regulatory affairs suppliers spotlight suppliers by sector a-z production & manufacturing fine & speciality chemicals manufacturing process & production otc drug research drug delivery drug discovery & development contract research & services clinical trials contract research contract services automation it & software laboratory instrumentation inward investment packaging regulatory affairs # a b c d e f g h i j k l m n o p q r s t u v w x y z -- -- -- pbr website usage about us accessibility advertise with us contact us help privacy rss feeds site map dining club browse by sector browse by network business review sites production & manufacturing drug research contract research & services automation fine & speciality chemicals manufacturing process & production otc drug delivery drug discovery & development clinical trials contract research contract services it & software laboratory instrumentation inward investment packaging regulatory affairs au

URL analysis for regulatoryaffairs.pharmaceutical-business-review.com

http://regulatoryaffairs.pharmaceutical-business-review.com/
http://regulatoryaffairs.pharmaceutical-business-review.com/news

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: PHARMACEUTICAL-BUSINESS-REVIEW.COM
Registry Domain ID: 96790032_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.lcn.com
Registrar URL: https://www.lcn.com
Updated Date: 2017-07-06T09:42:04+01:00
Creation Date: 2003-04-14T05:09:49+01:00
Registrar Registration Expiration Date: 2019-04-14T09:09:49+01:00
Registrar: LCN.com Ltd
Registrar IANA ID: 602
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +44.1438342490
Domain Status: clientDeleteProhibited
Domain Status: clientTransferProhibited
Domain Status: clientUpdateProhibited
Registry Registrant ID:
Registrant Name: PDMG Plc IT Department
Registrant Organisation: Progressive Digital Media Group Plc
Registrant Street: Progressive House
Registrant Street: 2 Maidstone Road
Registrant City: Foots Cray, Sidcup
Registrant State: Kent
Registrant Postal Code: DA14 5HZ
Registrant Country: GB
Registrant Phone: +44.2082697700
Registrant Email: [email protected]
Registry Admin ID: AI-727110
Admin Name: PDMG Plc IT Department
Admin Organisation: Progressive Digital Media Group Plc
Admin Street: Progressive House
Admin Street: 2 Maidstone Road
Admin City: Foots Cray, Sidcup
Admin State: Kent
Admin Postal Code: DA14 5HZ
Admin Country: GB
Admin Phone: +44.2082697700
Admin Email: [email protected]
Registry Tech ID: AI-300624
Tech Name: LCN Hostmaster
Tech Organization: LCN.com Ltd
Tech Street: Units H, J, K, Gateway 1000, Whittle Way
Tech City: Stevenage
Tech State/Province: Herts
Tech Postal Code: SG1 2FP
Tech Country: GB
Tech Phone: +44.1438342490
Tech Fax: +44.1438300137
Tech Email: [email protected]
Name Server: ns.tmnplc.com
Name Server: ns2.tmnplc.com
Name Server: ns3.tmngroup.com
Name Server: ns4.tmngroup.com
DNSSec: Unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-07-06T09:42:04+01:00 <<<

Domain Registration Service Provided By: LCN.com

The data in LCN.com's WHOIS database is provided by LCN.com for information
purposes, and to assist persons in obtaining information about or related to a
domain name registration record. LCN.com does not guarantee its accuracy.

By submitting a WHOIS query, you agree that you will use the data obtained only
for lawful purposes and that, under no circumstances will you use this data to:

(a) allow, enable, or otherwise support the transmission by e-mail, telephone,
or facsimile of mass, unsolicited, commercial advertising or solicitations to
entities other than the data recipient's own existing customers; or (b) enable
high volume, automated, electronic processes that send queries or data to the
systems of LCN.com, except as reasonably necessary to register domain names or
modify existing registrations.

By submitting this query, you agree to abide by this policy.

LCN.com reserves the right to modify these terms at any time.


*******************************************************************************
*******************************************************************************
** **
** Domain Registration Service Provided By: LCN.com **
** ------------------------------------------------ **
** **
** **
** - For award winning domain name services visit: **
** **
** https://www.lcn.com/domain_names **
** **
** - For powerful & reliable web hosting backed by a 30 day money **
** backed guarantee visit: **
** **
** https://www.lcn.com/web_hosting **
** **
** - For support visit: **
** **
** https://www.lcn.com/contact_us **
** **
*******************************************************************************
*******************************************************************************

  REGISTRAR LCN.COM LTD.

  REFERRER http://www.LCN.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =pharmaceutical-business-review.com

  PORT 43

  SERVER whois.lcn.com

  ARGS pharmaceutical-business-review.com

  PORT 43

  TYPE domain

DOMAIN

  NAME pharmaceutical-business-review.com

NSERVER

  NS.TMNPLC.COM 91.208.117.43

  NS2.TMNPLC.COM 91.208.117.43

  NS3.TMNGROUP.COM (DOES NOT EXIST)

  NS4.TMNGROUP.COM (DOES NOT EXIST)

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2017-03-09

  CREATED 2003-04-14

  EXPIRES 2019-04-14

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .